Rüschoff, Josef R.

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.lastpage","31"],["dc.bibliographiccitation.volume","34 Suppl 3"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Hegewisch-Becker, Susanna"],["dc.contributor.author","Höhler, Thomas"],["dc.contributor.author","Knoefel, Wolfram Trudo"],["dc.contributor.author","Kubicka, Stefan"],["dc.contributor.author","Lang, Hauke"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Luster, Markus"],["dc.contributor.author","Oettle, Helmut"],["dc.contributor.author","Reinacher-Schick, Anke"],["dc.contributor.author","Ridwelski, Karsten"],["dc.contributor.author","Riess, Hanno"],["dc.contributor.author","Rödel, Claus"],["dc.contributor.author","Rüschoff, Josef"],["dc.contributor.author","Schmiegel, Wolff"],["dc.contributor.author","Schmoll, Hans-Joachim"],["dc.contributor.author","Vanhoefer, Udo"],["dc.date.accessioned","2019-07-09T11:53:49Z"],["dc.date.available","2019-07-09T11:53:49Z"],["dc.date.issued","2011"],["dc.description.abstract","Der XI. Interdisziplinäre Expertenworkshop «Gastrointestinale Tumore», an dem 19 Vertreter der Fachbereiche internistische Onkologie, Gastroenterologie, Strahlentherapie, Chirurgie, Nuklearmedizin und Pathologie teilnahmen, bot einen Überblick über den aktuellen Stand der Wissenschaft im Bereich der gastrointestinalen Karzinome, wobei der Schwerpunkt auf dem Kolon-/Rektum- und Magenkarzinom lag, da in diesen Bereichen die meisten neuen Entwicklungen zu verzeichnen waren. Der Workshop versteht sich als ein interaktives Diskussionsforum zur aktuellen Standortbestimmung von Diagnostik und Therapie sowie zur Thesengenerierung für neue wissenschaftliche und therapeutische Ansätze. Schwerpunkte der diesjährigen Veranstaltung waren zum einen die adjuvante Therapie des Kolonkarzinoms und die First-Line-Therapie des metastasierten kolorektalen Karzinoms, denn in diesen Indikationen haben neue Studiendaten jetzt eine weitere Klärung des Therapiealgorithmus herbeigeführt. Darüber hinaus war die perioperative Therapie bei Lebermetastasen ein wichtiges Thema, zu dem aktuelle Studienkonzepte vorgestellt wurden. Des Weiteren wurde die HER2- Diagnostik beim Magenkarzinom intensiv diskutiert, denn diese unterscheidet sich deutlich von der beim Mammakarzinom. Bei korrekter Diagnostik ist das HER2-positive Magenkarzinom offenbar deutlich weiter verbreitet als bisher angenommen. Viel Beachtung fanden auch die Ergebnisse von 2 aktuellen Phase-III-Studien beim Pankreaskarzinom, die das therapeutische Vorgehen verändern werden und erstmals seit langem einen Fortschritt bei diesem schwer therapierbaren Tumor bedeuten dürften. Die wichtigsten Ergebnisse der 2-tägigen Diskussionsrunde sind im vorliegenden Supplement zusammengefasst."],["dc.identifier.doi","10.1159/000328047"],["dc.identifier.fs","582631"],["dc.identifier.pmid","21577036"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8060"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60502"],["dc.language.iso","de"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1423-0240"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.mesh","Clinical Trials as Topic"],["dc.subject.mesh","Evidence-Based Medicine"],["dc.subject.mesh","Gastrointestinal Neoplasms"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Interdisciplinary Studies"],["dc.subject.mesh","Medical Oncology"],["dc.title","Gastrointestinal tumors-interdisciplinary discussion over new data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Suelberg, Heiko"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T09:10:22Z"],["dc.date.available","2018-11-07T09:10:22Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009804441"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26471"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","Cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative triple treatment for rectal cancer (CET-CAPOX-RT-Phase-I/II Study): Influence on long-term survival and relevance of biomarkers"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","992"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","999"],["dc.bibliographiccitation.volume","87"],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Weiss, Christian"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Rau, Tillman"],["dc.contributor.author","Dellas, Kathrin"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Arnold, Dirk"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:17:13Z"],["dc.date.available","2018-11-07T09:17:13Z"],["dc.date.issued","2013"],["dc.description.abstract","Purpose: We have previously shown that the addition of cetuximab to chemoradiation therapy failed to improve complete response rates (pCR) in rectal cancer. Here we report the long-term results of the cetuximab added to preoperative radiation therapy with capecitabine and oxaliplatin (CET-CAPOX-RT) phase 1/2 study that evaluated preoperative chemoradiation with cetuximab, capecitabine, and oxaliplatin in patients with rectal cancer. Methods and Materials: The median follow-up was 63 months (range, 5-73 months). Sixty patients were enrolled; 3 patients were excluded due to protocol violation, and 4 died before surgery. Total mesorectal excision was performed in 53 patients, in 85% (n=45) with curative intention (M0-status). Secondary end points including overall survival (OS) disease-free survival (DFS) and cancer-specific survival (CSS) were calculated. The prognostic value of KRAS mutation status was also assessed. Results: Histopathological examination confirmed ypUICC stages 0 (n=4; pCR), I (n=17), II (n=10), III (n=14), and IV (n=8). For patients who underwent surgery (n=53), OS at 1, 3, and 5 years was 88.7%, 83%, and 75.5%, respectively, whereas CSS rates were 94.1%, 88.1%, and 78.1%, respectively. In the 45 patients who were treated with curative intent (M0), the OS rates at 1, 3, and 5 years were 91.1%, 88.9%, and 86.7%, respectively; whereas CSS rates were 97.6%, 95.2%, and 90.3%, respectively; and DFS rates were 90.7%, 88.3%, and 88.3%, respectively. We did not find any locoregional failure in patients with M0-status (n=45). Chronic toxicity was rare. KRAS mutations, as detected in 33.3%, showed no correlation with the clinicopathological parameters nor significance for either OS (P=.112), CSS (P=.264), or DFS (P=.565). Conclusions: Taken together, chemoradiation therapy combined with cetuximab is safe, feasible, and offers excellent survival rates. KRAS mutation status was not a predictive factor. Importantly, lack of improvement in pCR rate did not translate to poor survival in our clinical trial. (C) 2013 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2013.09.011"],["dc.identifier.isi","000327496600030"],["dc.identifier.pmid","24210078"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28108"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1879-355X"],["dc.relation.issn","0360-3016"],["dc.title","Preoperative Chemoradiation Therapy With Capecitabine/Oxaliplatin and Cetuximab in Rectal Cancer: Long-Term Results of a Prospective Phase 1/2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]